Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease

Gaucher Disease Clinical Trial

— LYSO-PROOF  

Official title:

Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease: An International, Multicenter, Epidemiological Protocol

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02416661
• Other study ID #: LP 06-2018
• Status: Completed
• Start date: August 27, 2018
• Est. completion date: January 15, 2021

Study information

• Verified date: April 2020
• Source: CENTOGENE GmbH Rostock
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

International, multicenter, epidemiological study to demonstrate the correlation and predictive value of lyso-Gb1 concentration with the clinical severity of naïve, initially non-ERT/SRT Gaucher disease type 1 and during the study ERT/SRT-newly started Gaucher type 1 patients and to correlate lyso-Gb1 concentration with the clinical improvement of ERT or SRT treated Gaucher type 1 and the clinical course of non-treated patients based on GD-DS3

Description:

Gaucher disease is an autosomal recessive inherited lysosomal storage disorder. The disease is caused by the hereditary deficiency of the glucocerebrosidase, a lysosomal enzyme that breaks down glucocerebroside into glucose and ceramide.

To date a definitive diagnosis of Gaucher's disease can only be made applying biochemical testing measuring the reduced enzymatic activity of the beta-glucosidase together with genetic confirmation. Since numerous different mutations may be the cause of a particular lysosomal storage disease the sequencing of the entire beta-glucosidase gene is applied in Gaucher's disease in order to confirm the genetic diagnosis.

The use of primary storage molecules as biomarker was assessed for glucosylceramide (Gb1) in plasma of Gaucher's disease patients and compared to the level of Gb1 in healthy individuals.

In order to establish a sensitive and specific biomarker for GD, we compared mass spectra of the plasma of healthy controls and GD patients using HPLC and tandem mass spectrometry. Mass spectra that differed most between patients and controls were analysed in more detail. The resulting biomarker, which was patented in June 2011 (PCT/EP2012/002409), was lyso - Gb1. We identified this compound as a reliable, sensitive and specific biomarker for GD in a cohort of GD patients. Furthermore, in a pilot study we evaluated whether lyso-Gb1 is related to the specific genotypes and is reliable for long-term monitoring of the efficiency of therapy.

The aim this study is therefore to investigate lyso-Gb1 as a long-term prognostic marker in naïve, non-ERT/SRT GD type 1 patients by monitoring over the course of 36 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 299
• Est. completion date: January 15, 2021
• Est. primary completion date: January 15, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Months and older

Eligibility

Inclusion Criteria:

• Male or female patients aged 6 months or older

• Patients with genetically confirmed diagnosis of Gaucher disease type 1

• No prior treatment with enzyme replacement therapy or substrate reduction therapy ro no traetment for more than 24 months

• Signed informed consent by parents/legal guardian and patient

Exclusion Criteria:

• Male or female patients being younger than 6 months

• Patients without genetically confirmed diagnosis of Gaucher disease type 1

• Gaucher disease 2 or 3

• Patient is currently undergoing enzyme replacement therapy or substrate reduction therapy

• Missing signed informed consent

Related Conditions & MeSH terms

• Gaucher Disease
• Lysosomal Storage Diseases
• Sphingolipidoses

Locations

Country	Name	City	State
Albania	University Hospital Center Mother Teresa	Tirana
Greece	Aristotle University of Thessaloniki, Ippokration General Hospital	Thessaloniki
India	Centre for Human Genetics	Bangalore
Israel	Shaare Zedek Medical Center	Jerusalem
Morocco	Children hospital	Rabat
Morocco	Hopital d'Enfant	Rabat
Pakistan	The Children's Hospital and the Institute of Child Health	Lahore	Punjab
Spain	Hospital Universitari de Bellvitge (planta 7.1)	Barcelona

Sponsors (1)

Lead Sponsor	Collaborator
CENTOGENE GmbH Rostock

Countries where clinical trial is conducted

Albania,  Greece,  India,  Israel,  Morocco,  Pakistan,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Demonstrating the correlation and predictive value of lyso-Gb1 concentration with the clinical severity of naïve, initially non-ERT/SRT Gaucher disease type 1 and during the study ERT/SRT-newly started Gaucher type 1 patients	lyso-Gb1 will be analzyed via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) and compared to merged control. The LC/MRM-MS is performed on an ABSciex 6500 triple quadrupole mass spectrometer, coupled with a Waters Acquity UPLC.	48 month
Secondary	Correlating lyso-Gb1 concentration with the clinical improvement of ERT or SRT treated Gaucher type 1 and the clinical course of non-treated patients based on GD-DS3.	lyso-Gb1 will be analysed over a period of 36 months via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) to demonstrate the course of the biomarker.	48 month

External Links

•   CENTOGENE is a rare disease company focused on transforming clinical, genetic, and biochemical data into medical solutions for patients